21717-96-4
21717-96-4
Chemical Structure
2-Amino-5-fluoropyridine
- CAS No.: 21717-96-4
- Formula:C5H5FN2
- Molecular Weight:112.11
IUPAC Name: 5-fluoropyridin-2-amine
InChIKey: YJTXQLYMECWULH-UHFFFAOYSA-N
SMILES: NC1=NC=C(F)C=C1
Biological Activity: 2-Amino-5-fluoropyridine is a pharmaceutical intermediate. 2-Amino-5-fluoropyridine can serve as a hinge-binding group of 2-Aminopyridine (HY-Y0174), resulting in a significant loss of PI3Kβ activity[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-Amino-5-fluoropyridine | 99.90% | 2-Amino-5-fluoropyridine is a pharmaceutical intermediate. 2-Amino-5-fluoropyridine can serve as a hinge-binding group of 2-Aminopyridine (HY-Y0174), resulting in a significant loss of PI3Kβ activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Woll MG, et al. Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 as a treatment for spinal muscular atrophy. Journal of medicinal chemistry. 2016 Jul 14;59(13):6070-85. [Content Brief]
- [2]. Maeda DY, et al. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. Journal of medicinal chemistry. 2014 Oct 23;57(20):8378-97. [Content Brief]
- [3]. Moslin R, et al. Identification of -Methyl Nicotinamide and -Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). Journal of medicinal chemistry. 2019 Oct 24;62(20):8953-8972. [Content Brief]
- [4]. Perreault S, et al. Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif. ACS medicinal chemistry letters. 2020 Jun 11;11(6):1236-1243. [Content Brief]
- [5]. Storer RI, et al. The discovery and evaluation of diaryl ether heterocyclic sulfonamides as URAT1 inhibitors for the treatment of gout. MedChemComm. 2016 Aug 1;7(8):1587-95.
- [6]. Hu PH, et al. Design, Synthesis and Anticancer Evaluation of 4H-Pyrido[1,2-a]pyrimidine-4-one-1,3,5-triazine Derivatives. ChemistrySelect. 2026;11(4):e202506134.
- [7]. Ku C, et al. Fluoropyridine modulated local charge distribution of carbon nitride to facilitate photocatalytic oxidative γ-valerolactone production. Applied Surface Science. 2025;679:161261.
